Patrys Limited
Level 6, Equitable House
343 Little Collins Street, Suite 614
Melbourne
Victoria
3000
Tel: 61-3-9670-3273
73 articles about Patrys Limited
-
Patrys Appoints Global Biotechnology Leader as Chairman - In Preparation for First Clinical Trial for Groundbreaking Cancer Therapy
11/18/2022
Patrys Limited, a therapeutic antibody development company, has announced the appointment of Dr. Charmaine Gittleson as the Chairman of the Board of Directors – a highly respected and experienced global biotechnology leader.
-
Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight
6/16/2021
Patrys Limited, a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic antibody candidate PAT-DX1 in The Journal of Clinical Investigation—Insight.
-
Patrys Limited Release: United States Patent Granted For Pre-clinical IgM Candidate PAT-LM1
10/11/2017
-
Patrys Limited Appointments To New Scientific Advisory Board
12/13/2016
-
Patrys Limited Appoints Dr. James Campbell As CEO
4/8/2015
-
Patrys Limited Provides Market Update
2/6/2015
-
Patrys Limited Provides Update On CEO Position
10/29/2014
-
Patrys Limited To Present At German Hematology Congress
8/18/2014
-
Patrys Limited Granted Third U.S. Patent For Lead Clinical Product PAT-SM6
6/18/2014
-
Patrys Limited Release: First Plant-Based Production Of PAT-SM6
4/2/2014
-
Patrys Limited PAT-LM1 Advancing To The Clinic
3/24/2014
-
Patrys Limited Raises A Further $0.9 Million
1/29/2014
-
Patrys Limited Release: PAT-SC1 Clinical Trial 10 Year Follow Up Data Published
1/22/2014
-
Patrys Limited Raises $5.5 Million Following Closure Of Rights Issue
12/16/2013
-
Data From Final Cohort Of Patients In Patrys Limited Multiple Myeloma Clinical Trial
12/2/2013
-
Patrys Limited Data to be Presented at American Society of Hematology International Conference
10/10/2013
-
Patrys Limited Release: PAT-SM6 Receives Orphan Drug Designation for Multiple Myeloma in Europe
9/12/2013
-
Patrys Limited Release: Data From 2nd and 3rd Cohorts of Patients in Multiple Myeloma Clinical Trial
8/13/2013
-
Patrys Limited's Multiple Myeloma Clinical Trial to Progress to Final Patient Group
8/7/2013
-
Patrys Limited Completes Treatment of Third Patient Group in Multiple Myeloma Trial
7/25/2013